Skip to main content
Fig. 1 | BMC Cancer

Fig. 1

From: Assessing frequency and clinical outcomes of BRCA mutated ovarian cancer in Saudi women

Fig. 1

Disease-free survival of ovarian cancer stratified by BRCA status for first-line therapy. The Kaplan–Meier estimator was used to determine DFS among patients with germline BRCA mutation and those without germline BRCA mutation. Two sided P values were calculated with the use of the stratified log rank test and CI denotes confidence interval. The median DFS was longer in the BRCA mutant women 25 (95% CI: 21.7–28.2) vs. 17 (95% CI: 8.7–25) months, (p = 0.02)

Back to article page